Intranasal pan-influenza sherpabody - Pandemblock
Latest Information Update: 23 Oct 2023
At a glance
- Originator Pandemblock
- Class Antivirals; Recombinant proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Influenza A virus infections; Influenza B virus infections
Highest Development Phases
- Research Influenza A virus infections; Influenza B virus infections
Most Recent Events
- 23 Oct 2023 Intranasal pan-influenza sherpabody is available for licensing as of 23 Oct 2023. https://pandemblock.com/partnering (Pandemblock website, October 2023)
- 23 Oct 2023 Early research in Influenza A virus infections (Prevention) in Finland (Intranasal) prior to October 2023 (Pandemblock pipeline, October 2023)
- 23 Oct 2023 Early research in Influenza B virus infections (Prevention) in Finland (Intranasal) prior to October 2023 (Pandemblock pipeline, October 2023)